Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in ACPA-Positive Difficult-to-Treat Rheumatoid Arthritis (Phase 2b Randomized Withdrawal Study)
2024-515973-82-00Phase 2Authorised
- Sponsor
- Immunovant, Inc.
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing IMVT-1402 arm with Placebo arm (2 arms). Primary endpoint: ACR20 response at Week 28. Planned start May 2025; status: authorised.
02
Drugs
IMVT-1402
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-515973-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515973-82-00.